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Abstract
Lung transplantation is an important treatment option for patients with advanced lung disease. Survival rates for
lung transplant recipients have improved; however, the major obstacle limiting better survival is bronchiolitis
obliterans syndrome (BOS). In the last decade, survival after lung retransplantation has improved for transplant
recipients with BOS. This manuscript reviews BOS along with the current therapeutic strategies, including recent
outcomes for lung retransplantation.
Introduction
Lung transplantation is a treatment option for patients
with advanced lung disease or irreversible pulmonary
failure. Despite advancements in surgical techniques,
lung preservation, immunosuppression, and manage-
ment of ischemia/reperfusion injury and infections,
acute and chronic allograft rejection continues to be a
major problem. The incidence and severity of acute
rejection in lung transplantation exceeds all other solid
organ transplants [1,2]. Chronic rejection, more com-
monly called bronchiolitis obliterans syndrome (BOS), is
the leading cause of death beyond the first year post
lung transplantation [3,4]. The key clinical feature of
BOS is the development of airway obstruction with a
reduction of forced expiratory volume in 1 second
(FEV1) that does not respond to bronchodilators (Table
1) [5,6]. The hallmark histological findings of chronic
rejection is obliterative bronchiolitis (OB), which is an
inflammatory process affecting small noncartilagenous
airways [7,8]. Figure 1 is representative of the typical
findings of OB histopathologically. The development of
BOS is rare within the first year after lung transplant,
but the cumulative incidence ranges from 43 to 80%
within the first five years of transplantation [4,9-11].
Diagnosis
The diagnosis of BOS is typically made by clinical,
physiological, and radiographic parameters. Due to the
sporadic or patchy involvement of OB, pathologic
diagnosis can be missed by transbronchial biopsies
(TBB) [5], which are often performed to exclude other
diagnoses including acute rejection or infection. Histo-
logically, early lesions of BOS demonstrate submucosal
lymphocytic inflammation and disruption of the
epithelium of small airways, followed by an ingrowth
of fibromyxoid granulation tissue into the airway
lumen, resulting in partial or complete obstruction.
Subsequently, granulation tissue organizes in a cicatri-
cial pattern with resultant fibrosis and thus obliterates
t h ea i r w a yl u m e n[ 1 2 ] .I ns o m ei n s t a n c e s ,t h eo n l y
residual histologic evidence of BOS is a ring of circum-
ferential elastin around an otherwise undetectable air-
way, what is termed the “vanishing airways disease”
[12].
As a result of histologic variability, the International
Society for Heart and Lung Transplant (ISHLT) devel-
oped standard nomenclature and made a distinction
between documented OB and BOS [13]. An ad hoc
working group was established under the auspices of the
ISHLT for the purpose of developing a clinically applic-
able system and published their original recommenda-
tions in 1993 [13]. The group concluded that the FEV1
was the most reliable and consistent indicator of allo-
graft dysfunction, excluding other identifiable causes
with the adoption of the term BOS to describe such dys-
function, recognizing that there may or may not be
pathologic evidence of OB present [13]. The group also
defined 4 stages of BOS, each with 2 subcategories to
indicate whether pathologic evidence of OB had been
identified [13].
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onset and gradual decline in pulmonary function over
months to years to abrupt onset with severe decline in
pulmonary function over a few weeks [14-16]. The clini-
cal diagnosis of BOS requires a sustained pulmonary
decline with a reduced FEV1 for more than 3 weeks and
the exclusion of acute allograft rejection, anastomotic
complications or stricture, infection, or other disease
affecting pulmonary function. In comparison, acute allo-
graft rejection is defined as perivascular or peribronchial
mononuclear inflammation that may be associated with
an acute reduction in pulmonary function. Clinical pre-
sentation of acute allograft rejection may vary from
asymptomatic patients with acute rejection found on sur-
veillance biopsy to non-specific symptoms including
cough, dyspnea, sputum production, fever, hypoxia, and
adventitious sounds on lung auscultation [8,15]. The cur-
rent classification of BOS is based on changes in FEV1
with the maximum post-transplant FEV1 being assigned
a 100% predicted value (the mean of the two best post-
operative FEV1 values with at least 3 weeks between the
measurements) and the reduction in the mean forced
expiratory flow during the middle half of the forced vital
capacity (FEF25-75%) used as an early marker for BOS or
potential BOS [5]. The current ISHLT classification sys-
tem for BOS is outlined in Table 1.
Currently, radiographic imaging is not used as a diag-
nostic tool in transplant recipients when evaluating for
BOS; however, high resolution computed tomography
(HRCT) imaging with inspiratory and expiratory views
may be helpful when considering the diagnosis. Numer-
ous abnormalities may be seen including hyperlucency
or air-trapping, bronchiectasis, thickening of septal lines,
mosaic pattern of attenuation, or tree-in-bud pattern
[17]. Obtaining an expiratory CT scan may help reveal
air-trapping that is not evident on inspiratory scans in
BOS [17,18]. Furthermore, the extent of air-trapping
may correlate with BOS severity [18].
Pathogenesis and Risk Factors for BOS
The pathogenesis of BOS is complex and involves both
alloimmune and non-alloimune mechanisms that occur
alone or in combination. Chronic rejection is classified
pathologically as either chronic vascular rejection or
chronic airway rejection [7]. Chronic vascular rejection,
the less common manifestation of rejection, involves the
development of atherosclerosis in the pulmonary vascu-
lature [7]. Chronic airway rejection, which is defined as
OB histologically, is seen more frequently and results in
increased morbidity and mortality [7,19]. Table 2 sum-
marizes the current reported risk factors associated with
the development of BOS in lung transplant recipients.
The major risk factors associated with BOS are reviewed
in the following paragraphs.
Acute rejection
Acute rejection is well defined as a primary risk factor
in the development of BOS [9,20-25]. Recurrent, late,
and severe episodes of acute rejection have all been
associated with an increased risk for BOS. Moreover,
Hachem et al [26] recently demonstrated that a single
episode of minimal acute rejection without recurrence
or progression to a higher grade of rejection was a sig-
nificant predictor of BOS independent of other risk
factors.
Table 1 Bronchiolitis obliterans syndrome (BOS)
classification
BOS Stage Classification
0 FEV1 > 90% of baseline & FEF25-75% > 75% of baseline
0-p* FEV1 81-90% of baseline &/or FEF25-75% ≤ 75% of baseline
1 FEV1 66-80% of baseline
2 FEV1 51-65% of baseline
3 FEV1 ≤ 50% of baseline
*0-p = potential BOS, Modified from Reference #6
Figure 1 Representative histopathology of obliterative
bronchiolitis with inflammation and fibrosis of the airway with
sparing of the surrounding alveoli (Hematoxylin and Eosin
stain).
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Pneumonia and/or airway colonization with gram posi-
tive and gram negative pathogens as well as fungi are
independent determinants of chronic allograft dysfunc-
tion [27]. In an interesting study, serology to Chlamydia
pneumoniae in donors and recipients was associated
with the development of BOS in lung transplant recipi-
ents. In fact, BOS occurred more frequently and earlier
in C. pneumoniae seropositive donors, and the reverse
was true in seronegative recipients [28]. In another
study, colonization of the lower airways with Aspergillus
was also determined to be a potential causative role for
the development of BOS post-lung transplantation [29].
Exudative bronchiolitis, as determined by HRCT ima-
ging, was associated with an increased risk of BOS in
lung transplant recipients [30].
Type of transplant
The type of transplant, whether single or bilateral, may
be a risk factor for the development of BOS. In a retro-
spective review of 221 lung transplant recipients with
chronic obstructive pulmonary disease (COPD), bilateral
transplant recipients were more likely to be free of BOS
than single recipients three years (57.4% vs 50.7%) and
five years (44.5% vs 17.9%) after transplantation (P =
0.024) [31].
Viral infection
Lower respiratory tract infections due to community
acquired respiratory viruses have been reported to
increase the risk for BOS, including rhinovirus, corona-
virus, respiratory syncytial virus, influenza A, parain-
fluenza, human metapneumovirus, and human herpes
virus-6 [32-35]. Therefore, treatment of these viral infec-
tions theoretically may reduce the incidence of BOS, but
data are limited [36]. Cytomegalovirus (CMV) infection
has also been well described as a potential risk factor in
the development of BOS; [19,37,38] however, one study
demonstrated that histopathologically confirmed CMV
pneumonia treated with ganciclovir was not a risk factor
for BOS or patient survival nor was any particular CMV
serologic donor/recipient group [39]. The treatment of
CMV and the subsequent prevention of BOS remains
unclear. In a more recent study, Epstein-Barr virus
(EBV) reactivation detection by repeated EBV DNA ana-
lysis of blood in lung transplant recipients was asso-
ciated with the development of BOS [40].
Primary graft dysfunction
Ischemia-reperfusion injury after lung transplantation or
primary graft dysfunction was associated with the later
development of BOS [41-43]. Daud et al [43] reported
that out of 334 lung allograft recipients, 269 had pri-
mary graft dysfunction: 130 had grade 1, 69 had grade
2, and 70 had grade 3. A multivariable model demon-
strated that the increased risk for BOS with primary
graft dysfunction was independent of acute rejection,
lymphocytic bronchitis, and community-acquired
respiratory viral infections [43]. Furthermore, this
increased risk of BOS was directly related to the severity
of primary graft dysfunction [43].
Gastroesophageal reflux
Gastroesophageal (GE) reflux is very common post-lung
transplant and may contribute to chronic allograft rejec-
tion. The mechanism by which GE reflux contributes to
BOS remains unclear. The presence of bile acids and
pepsin in bronchoalveolar lavage (BAL) fluid from lung
transplant recipients suggests that aspiration may elicit
airway injury [44,45]. Moreover, treatment with proton
pump inhibitors reduced acid reflux but did not affect
nonacid reflux, including bile or pepsin, suggesting the
presence of these elements in the lower airways as fac-
tors associated with BOS [45]. Early surgical treatment
of GE reflux with fundoplication after lung transplanta-
tion has been associated with greater freedom from BOS
Table 2 Risks factors for bronchiolitis obliterans syndrome after lung transplantation.
Probable Potential
Acute rejection Aspergillus colonization of the lower airways
CMV pneumonitis Aspiration
HLA-mismatching CMV infection (without pneumonitis)
Lymphocytic bronchitis/bronchiolitis Donor antigen-specific activity
Noncompliance with medications Epstein-Barr virus reactivation
Primary graft dysfunction Etiology of native lung disease
Gastroesophageal reflux
Older donor age
Pneumonia (gram negatives, gram positives, fungi)
Prolonged allograft ischemia
Recurrent infection other than CMV
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study reported that 93/128 (73%) of lung transplant reci-
pients had abnormal ambulatory 24-hour esophageal pH
probe results [46]. After fundoplication, 16 patients had
improved BOS scores, with 13 of these patients no
longer meeting the criteria for BOS [46]. Another small
study demonstrated that early aggressive surgical treat-
ment of GE reflux with fundoplication not only
improved rates of BOS but also survival [47].
Human leukocyte antigen mismatches
The effect of human leukocyte antigen (HLA) mis-
matches upon the development of BOS has been
reported but remains controversial. The development of
anti-HLA class I and II antibodies was associated with
BOS [15,48,49]. Furthermore, an association between
BOS and mismatches at the A locus [21,50], two DR
mismatches [51], or total mismatches at the A locus, B
locus, or DR locus [9,50] are reported. However, mis-
matches at the HLA A locus but not the B locus were
associated with acute cellular rejection but not BOS
[52]. Further research is needed to investigate this very
important issue.
Autoimmunity
An emerging concept regarding BOS is the possibility of
autoimmunity rather than alloimmunity to hidden epi-
topes of collagen type V. These epitopes are exposed as
a result of ischemia and reperfusion injury or other
insults that may damage the respiratory epithelium [53].
Further research is ongoing to investigate these impor-
tant findings.
Therapies for BOS
Immunosuppressant therapy
A small number of studies have assessed the different
therapeutic modalities that are reportedly beneficial in
these patients. Adjustments in immunosuppressant ther-
apy and the use of immunomodulating medications are
potential therapeutic options. Adjustments in the immu-
nosuppressive agents have demonstrated some positive
outcomes [54-58]. Cairn et al [54] reported that the
conversion of cyclosporine to tacrolimus stabilized
spirometric measurements in patients with BOS while
Whyte et al [55] demonstrated similar results with the
introduction of mycophenolate mofetil. In one study,
BOS was less likely to progress when sirolimus was sub-
stituted for azathioprine in 37 lung transplant recipients
receiving cyclosporine or tacrolimus, but the sirolimus
had to be discontinued due to side effects [56].
Novel or emerging therapies
The use of other immunosuppressant therapies in novel
ways may improve outcomes for BOS. There is evolving
research in the use of aerosolized cyclosporine [59-61].
A single-center, randomized, double-blind, placebo-con-
trolled trial of aerosolized cyclosporine was performed
with initiation of the drug within six weeks after lung
transplant along with routine systemic immunosuppres-
sion [59]. Aerosolized cyclosporine did not improve the
rate of acute rejection but improved survival and
extended periods of chronic rejection-free survival [59].
More recently, a single center randomized study demon-
strated improvement in the pulmonary function of lung
transplant patients who received aerosolized cyclospor-
ine for the first 2 years after transplantation compared
to placebo [60]. A recent case report demonstrated that
aerosolized tacrolimus was associated with improvement
in both functional capacity and oxygenation in a patient
with BOS [62]. There are other therapies under investi-
gation, including alemtuzumab, an anti-CD 52 antibody,
which significantly improved the histological grade of
BOS in 7 of 10 patients but had no impact on pulmon-
ary function in an open label study [63].
Azithromycin therapy
Azithromycin displays immunomodulatory effects that
seem to be beneficial in several pulmonary disorders,
including BOS. Three studies showed the value of pro-
longed azithromycin (250 mg orally every other day) in
a total of 34 patients with BOS with an improvement in
the FEV1 for some patients but not all [64-66]. In a lar-
ger observational study, Gottlieb et al [67]. demon-
strated that 24/81 (30%) patients with BOS had
improvement in the FEV1 after 6 months of azithromy-
cin therapy; 22 of the 24 responders improved after only
3m o n t h so ft h e r a p y .W i t hu n i v a r i a t ea n a l y s i s ,a z i t h r o -
mycin responders at 6 months demonstrated higher pre-
treatment BAL neutrophils [67]. Neurohr et al [68] also
demonstrated that BAL neutrophilia in stable lung
transplant recipients had a predictive value in the identi-
fication of BOS.
Statin therapy
Statins (3-Hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors) are widely used lipid lowering agents
that have demonstrated immunomodulatory effects. The
6-year survival of lung transplant recipients receiving
statin therapy was much greater than patients not on
statin therapy [69]. Acute rejection was less frequently
found in the statin group; none of the 15 recipients
started on statin therapy during the first postoperative
year developed OB, whereas the cumulative incidence
among control subjects was 37%.
Extracorporeal photopheresis
There is evidence that extracorporeal photopheresis is
an effective method of treatment of any inflammatory
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late 1990’s, two studies demonstrated the stabilization of
airway obstruction due to BOS with extracorporeal
photopheresis in 4/5 patients [70] and 5/8 patients [71],
respectively, without complications occurring from the
procedure. In fact, Salerno et al [71] reported 2 patients
having histologic reversal of rejection. Functional stabili-
zation was observed in 3/5 patients with BOS that was
accompanied by a slight increase or stabilization of the
number of peripheral blood CD4(+)CD25(high) cells
with in vitro features of Treg cells while the other 2
non-responsive patients with BOS showed a decline in
the peripheral Treg subset [72]. An animal study further
confirmed that CD4(+)CD25(+) T cells appears to play a
key role in the immunomodulatory effects of extracor-
poreal photopheresis [73]. Over a 10-year period, one
study reported that 12 patients with BOS treated with
extracorporeal photopheresis had significant improve-
ment in the decline in FEV1, 112 mL/month before
therapy and 12 mL/month after 12 cycles of therapy (P
= 0.011) [74]. The effect of extracorporeal photopheresis
on absolute FEV1 on the group of 12 patients was not
significant and the therapy was tolerated [74].
More recently, 60 lung transplant recipients experi-
enced a reduction in the rate of decline in lung function
associated with progressive BOS with extracorporeal
photopheresis therapy [75]. The decline in FEV1 6
months prior to treatment with extracorporeal photo-
pheresis was 116.0 mL/month, but the slope decreased
to 28.9 mL/month during the 6-month period after
initiation of therapy with the mean difference in the rate
of decline being 87.1 mL/month (P < 0.0001) [75].
Furthermore, the FEV1 actually improved in 25.0% of
patients after starting extracorporeal photopheresis with
a mean increase of 20.1 mL/month [75].
Management Strategies in BOS
An important therapeutic strategy in treating BOS is
initial prevention and aggressive treatment of known
associated factors, as well as early identification of BOS
in order to immediately begin available therapies. Initi-
ally, the clinical management of these patients should
focus on risk reduction of primary graft dysfunction by
decreasing mechanical ventilation time for donors and
reducing allograft ischemia time, while also limiting car-
diopulmonary bypass and blood product transfusions
during transplantation [76].
Routine screening to define the onset of BOS is very
important as there appears to be a therapeutic window for
some of the treatment options available. Jain et al [77]
demonstrated that azithromycin treatment initiated before
the development of BOS stage 2 was independently asso-
ciated with a significant reduction in the risk of death.
Thus, clinicians should be closely monitoring lung
transplant recipients, carefully monitoring for early
chronic rejection. Spirometry should be performed routi-
nely on lung transplant recipients, looking for any changes
in the FEV1 and FEF25-75% measurements based on the
ISHLT classification system (Table 1). The use of HRCT
imaging with inspiratory and expiratory views of the chest
to assess for airtrapping may be helpful based on initial
studies [18,78], but further research is less conclusive
regarding its value [79-81]. Currently, radiographic ima-
ging remains supportive in the diagnostic evaluation and
management of BOS. Figure 2 demonstrates the usefulness
of HRCT imaging in diagnosing BOS in a 55 year-old
patient who underwent right single lung transplantation in
1992 for alpha-1-antitrypsin deficiency but suddenly devel-
oped a 25% reduction in FEV1 3 years after undergoing
single left lung transplantation for BOS. The right allograft
clearly had significant bronchiectasis due to long-standing
BOS, but the more recent allograft on the left side had
signs of bronchiectasis with airtrapping, further supporting
the diagnosis of BOS in that allograft.
Aggressive treatment of GE reflux, avoidance of infec-
tion, and timely vaccinations are instrumental in managing
lung transplant recipients. Experimental risk factors
reported in BOS should be considered from a clinical
standpoint during the evaluation of transplant recipients,
including higher bronchoalveolar (BAL) neutrophilia and
IL-8 levels [82,83] as well as airway colonization with
Pseudomonas aeruginosa [84,85]. Further research is
Figure 2 High resolution CT scan of the chest demonstrating
bilateral bronchiectasis (right more severe than left) in a
patient who underwent right single lung transplantation in
1992 for alpha-1-antitrypsin deficiency and left single lung
transplantation in 2003 for bronchiolitis obliterans syndrome.
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factors.
Retransplantation for BOS
The definitive treatment for BOS and resulting bronch-
iectasis is retransplantation. However, lung retransplan-
tation remains very controversial due to limited organ
availability and lower survival rates as compared to
initial transplants. In 1995, Novick et al [86] reviewed
the records of 72 patients who underwent retransplanta-
tion for BOS at 26 North American and European cen-
ters. In this cohort, the actuarial survival rates were 71%
at 1 month, 43% at 1 year, and 35% at 2 years [86]. For
the 90-day postoperative survivors, 63% were alive 2
years after retransplantation [86]. Further study in larger
cohorts of 139 retransplant recipients in 1995 and 230
retransplant recipients in 1998 demonstrated very simi-
lar survival statistics [87,88]. Although survival rates for
lung retransplantation were lower than survival rates for
initial transplants, lung retransplantation continued to
be performed in recipients who developed BOS. More
recently, survival rates after lung retransplantation have
improved [89-94]. A retrospective cohort study of 205
patients who underwent lung retransplantation between
January 2001 and May 2006 in the United States
demonstrated a 1-year survival of 62%, 3-year survival of
49%, and 5-year survival of 45% [89]. These authors did
not assess the outcomes of patients undergoing retrans-
plantation specifically for BOS, but there was definite
improvement in outcomes for all patients after lung
retransplantation in the modern era. Moreover, there
have been smaller studies that have addressed the survi-
val of lung retransplantation for BOS in adult patients;
Table 3 outlines these research studies published since
2000. These 5 recent studies report 1-year and 5-year
survival rates at 60-75% and 44-62%, respectively in
comparison to the current unadjusted survival rates for
initial transplants of 79% at 1 year and 52% at 5 years as
published by Christie et al [4].
Conclusions
For lung transplant recipients, BOS remains to be the
primary cause of mortality after the first year. In the
current lung allocation score era of lung transplantation,
recipients have significantly fewer BOS-free days after 3-
year follow-up [95]. Further research is needed to better
define the pathophysiologic mechanisms in BOS in
order to either prevent or delay onset of the disorder.
The therapies available for BOS currently are very lim-
ited and serve only to slow the decline in pulmonary
function. Lung retransplantation continues to be contro-
versial, but survival rates have improved in patients with
BOS over the past decade and thus should be consid-
ered as a treatment option in this patient population.
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